Vertex shares rise after JPM sets Overweight rating
J.P. Morgan upgraded Vertex Pharmaceuticals to an Overweight rating and set a December 2027 price target of $560. VRTX stock was up 1.6% premarket.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.